IDEAYA Biosciences Appoints Douglas B. Snyder as Senior Vice President, General Counsel
IDEAYA Biosciences (NASDAQ: IDYA) has appointed Douglas B. Snyder as Senior Vice President and General Counsel, effective September 18, 2024. Snyder brings over 25 years of legal experience in healthcare, including roles at GW Pharmaceuticals, Actelion Pharmaceuticals, Eisai, GSK, and the FDA. His extensive commercial and international experience positions him well to lead IDEAYA's legal functions as the company prepares for potential commercialization of Darovasertib and expands its clinical pipeline efforts, including in MTAP-deletion.
Snyder's most recent role was Executive VP, Chief Legal Officer, and Secretary at GW Pharmaceuticals from 2017 to 2022, overseeing its $7.2 billion acquisition by Jazz Pharmaceuticals. He holds a J.D. from the Catholic University of America and a B.A. from Dickinson College.
IDEAYA Biosciences (NASDAQ: IDYA) ha nominato Douglas B. Snyder come Vicepresidente Senior e Consigliere Generale, con effetto dal 18 settembre 2024. Snyder porta con sé oltre 25 anni di esperienza legale nel settore della salute, avendo ricoperto ruoli presso GW Pharmaceuticals, Actelion Pharmaceuticals, Eisai, GSK e la FDA. La sua ampia esperienza commerciale e internazionale lo posiziona bene per guidare le funzioni legali di IDEAYA mentre l'azienda si prepara per la possibile commercializzazione di Darovasertib e amplia i suoi sforzi nella pipeline clinica, inclusa la delezione di MTAP.
Il ruolo più recente di Snyder è stato quello di Vicepresidente Esecutivo, Consigliere Legale Capo e Segretario presso GW Pharmaceuticals dal 2017 al 2022, supervisionando l'acquisizione da 7,2 miliardi di dollari da parte di Jazz Pharmaceuticals. Ha conseguito un J.D. presso la Catholic University of America e una B.A. presso Dickinson College.
IDEAYA Biosciences (NASDAQ: IDYA) ha nombrado a Douglas B. Snyder como Vicepresidente Senior y Asesor General, con efecto a partir del 18 de septiembre de 2024. Snyder aporta más de 25 años de experiencia legal en el sector salud, incluyendo roles en GW Pharmaceuticals, Actelion Pharmaceuticals, Eisai, GSK y la FDA. Su amplia experiencia comercial e internacional lo posiciona bien para liderar las funciones legales de IDEAYA mientras la compañía se prepara para la posible comercialización de Darovasertib y expande sus esfuerzos en la pipeline clínica, incluida la eliminación de MTAP.
El papel más reciente de Snyder fue como Vicepresidente Ejecutivo, Asesor Legal Principal y Secretario en GW Pharmaceuticals desde 2017 hasta 2022, supervisando su adquisición de 7.2 mil millones de dólares por Jazz Pharmaceuticals. Tiene un J.D. de la Catholic University of America y una B.A. de Dickinson College.
IDEAYA Biosciences (NASDAQ: IDYA)는 Douglas B. Snyder를 수석 부사장 겸 법률 고문으로 임명하며, 이는 2024년 9월 18일부터 시행됩니다. Snyder는 GW Pharmaceuticals, Actelion Pharmaceuticals, Eisai, GSK 및 FDA에서의 역할을 포함하여 의료 분야에서 25년 이상의 법률 경험을 가지고 있습니다. 그의 폭넓은 상업적 및 국제 경험은 IDEAYA가 Darovasertib의 상업화를 준비하고 MTAP 결실 작업을 포함한 임상 파이프라인 노력을 확장하는 데 있어 법률 기능을 이끌기 좋은 조건을 갖추고 있습니다.
Snyder의 최근 역할은 2017년부터 2022년까지 GW Pharmaceuticals의 사장, 수석 법률 고문 및 비서로서 Jazz Pharmaceuticals에 의해 72억 달러의 인수를 감독하는 것이었습니다. 그는 Catholic University of America에서 J.D.를, Dickinson College에서 B.A.를 받았습니다.
IDEAYA Biosciences (NASDAQ: IDYA) a nommé Douglas B. Snyder au poste de Vice-Président Senior et Conseiller Général, avec effet au 18 septembre 2024. Snyder apporte plus de 25 ans d'expérience juridique dans le secteur de la santé, ayant occupé des postes chez GW Pharmaceuticals, Actelion Pharmaceuticals, Eisai, GSK et la FDA. Son expérience commerciale et internationale étendue le positionne bien pour diriger les fonctions juridiques d'IDEAYA alors que l'entreprise se prépare à une éventuelle commercialisation de Darovasertib et élargit ses efforts en matière de pipelines cliniques, y compris la délétion de MTAP.
Le dernier poste de Snyder était celui de Vice-Président Exécutif, Conseiller Légal Principal et Secrétaire chez GW Pharmaceuticals de 2017 à 2022, supervisant son acquisition de 7,2 milliards de dollars par Jazz Pharmaceuticals. Il détient un J.D. de la Catholic University of America et une B.A. du Dickinson College.
IDEAYA Biosciences (NASDAQ: IDYA) hat Douglas B. Snyder zum Senior Vice President und General Counsel ernannt, mit Wirkung zum 18. September 2024. Snyder bringt über 25 Jahre Erfahrung im Rechtsbereich im Gesundheitswesen mit, darunter Rollen bei GW Pharmaceuticals, Actelion Pharmaceuticals, Eisai, GSK und der FDA. Seine umfangreiche kommerzielle und internationale Erfahrung positioniert ihn gut, um die rechtlichen Funktionen von IDEAYA zu leiten, während das Unternehmen sich auf die potenzielle Kommerzialisierung von Darovasertib vorbereitet und seine klinischen Pipeline-Bemühungen, einschließlich der MTAP-Löschung, ausweitet.
Snyders zuletzt ausgeübte Rolle war die des Executive VP, Chief Legal Officer und Secretary bei GW Pharmaceuticals von 2017 bis 2022, wo er die Übernahme durch Jazz Pharmaceuticals im Wert von 7,2 Milliarden Dollar überwachte. Er besitzt einen Juris Doctor (J.D.) von der Catholic University of America und einen Bachelor of Arts (B.A.) vom Dickinson College.
- Appointment of experienced legal professional with over 25 years in healthcare
- Expertise in commercialization and international operations
- Experience with high-value acquisitions (GW Pharmaceuticals $7.2B, Actelion $30B)
- None.
- Over 25 years of legal experience with leading healthcare organizations, including GW Pharmaceuticals, Actelion Pharmaceuticals, Eisai, GSK, and the
U.S. FDA
"Doug brings a broad legal background in the healthcare field spanning biotechnology, pharmaceuticals and the FDA. He has developed extensive commercial and international experience across multiple organizations that makes him well-equipped to lead IDEAYA's legal functions as we continue to build a leading global precision medicine oncology company," said Yujiro S. Hata, President and Chief Executive Officer of IDEAYA Biosciences.
"I am excited to join IDEAYA during this exciting growth phase as the company prepares for potential commercialization of Darovasertib and broadens its clinical pipeline efforts, including in MTAP-deletion. I look forward to partnering with the management team and the broader organization to advance our collective mission to deliver transformative precision medicines to cancer patients," said Douglas B. Snyder.
Mr. Snyder most recently served as Executive Vice President, Chief Legal Officer and Secretary at GW Pharmaceuticals (NASDAQ: GWPH) from 2017 to 2022 through the
About IDEAYA Biosciences
IDEAYA is a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets.
Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to the Company's potential commercialization of Darovasertib and efforts to broaden its clinical pipeline. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's Annual Report on Form 10-K dated February 20, 2024 and any current and periodic reports filed with the
Investor and Media Contact
IDEAYA Biosciences
Andres Ruiz Briseno
SVP, Head of Finance and Investor Relations
investor@ideayabio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-appoints-douglas-b-snyder-as-senior-vice-president-general-counsel-302250621.html
SOURCE IDEAYA Biosciences, Inc.
FAQ
Who is Douglas B. Snyder and what is his new role at IDEAYA Biosciences (IDYA)?
What are IDEAYA Biosciences' (IDYA) current focus areas mentioned in the press release?
What was Douglas B. Snyder's most recent position before joining IDEAYA Biosciences (IDYA)?
How does Douglas B. Snyder's experience align with IDEAYA Biosciences' (IDYA) goals?
